Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Non-Current Liabilities (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Other Non-Current Liabilities for 7 consecutive years, with $138000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 66.34% to $138000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $138000.0 through Dec 2025, down 66.34% year-over-year, with the annual reading at $138000.0 for FY2025, 66.34% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $138000.0 at 4D Molecular Therapeutics, down from $144000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $1.9 million in Q2 2021, with the low at $23000.0 in Q3 2022.
  • Average Other Non-Current Liabilities over 5 years is $375650.0, with a median of $221500.0 recorded in 2022.
  • The sharpest move saw Other Non-Current Liabilities plummeted 95.77% in 2022, then soared 1504.35% in 2023.
  • Over 5 years, Other Non-Current Liabilities stood at $120000.0 in 2021, then skyrocketed by 76.67% to $212000.0 in 2022, then rose by 16.98% to $248000.0 in 2023, then skyrocketed by 65.32% to $410000.0 in 2024, then plummeted by 66.34% to $138000.0 in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $138000.0, $144000.0, and $334000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.